ReviewWorld journal of gastroenterology2015
Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 133 citations in OpenAlex.
- Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers.World journal of gastrointestinal oncology · 2024Trial
- A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.Scientific reports · 2024Trial
- Completion of perioperative chemotherapy and tumor regression grade as independent predictors of one-year survival after total gastrectomy for gastric cancer: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Astragalus polysaccharide-based nano-platforms loading PTX to boost chemo-immunotherapy for triple-negative breast cancer with intrinsic GLUT-targeting ability and immunoregulatory activity.Journal of nanobiotechnology · 2025Article
- Clinical utility of the peritoneal pathologic regression in gastric cancer patients associated to peritoneal metastasis. a study protocol.Pleura and peritoneum · 2025Article
- Impact of Treatment Modalities on Locally Advanced Gastric Cancer-Real-World Data.Current oncology (Toronto, Ont.) · 2025Article
- Role of Neoadjuvant Therapy in Remodeling Surgical Approaches for Gastrointestinal Malignancies.Current gastroenterology reports · 2025Review
- Identifying beneficial gastric cancer patient on prognosis after treating with perioperative or postoperative-only chemotherapy: a single-center real-world study.World journal of surgical oncology · 2025Article
- A novel ypN-TRG staging system for gastric cancer patients after neoadjuvant therapy based on the metro-ticket paradigm: a multicenter and large sample retrospective analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- The role of UPK1B in gastric cancer: multi-omics analysis and experimental validation.Discover oncology · 2025Article
- Risk analysis of cardiovascular mortality after gastric cancer diagnosis: a large population-based study.Frontiers in cardiovascular medicine · 2025Article
- Identification of lncRNAInternational journal of genomics · 2025Article
- Single-cell sequencing analysis revealed that WDR72 was a novel cancer stem cells related gene in gastric cancer.Heliyon · 2024Article
- Does total omentectomy prevent peritoneal seeding for advanced gastric cancer with serosal invasion?Surgical endoscopy · 2024Article
- Deep learning model for predicting postoperative survival of patients with gastric cancer.Frontiers in oncology · 2024Article
- Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer: A Two-Center Study on Romanian Population.Life (Basel, Switzerland) · 2023Article
- Comprehensive analysis of anoikis-related genes in prognosis and immune infiltration of gastric cancer based on bulk and single-cell RNA sequencing data.Journal of cancer research and clinical oncology · 2023Article
- Deltonin enhances gastric carcinoma cell apoptosis and chemosensitivity to cisplatinWorld journal of gastrointestinal oncology · 2023Article
- Article
- Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Over the last 15 years, there have been major advances in the multimodal treatment of gastric cancer, in large part due to several phase III studies showing the treatment benefits of neoadjuvant and adjuvant chemotherapy and chemoradiation protocols. The objective of this editorial is to review the current high-level evidence supporting the use of chemotherapy, chemoradiation and anti-HER2 agents in both the neoadjuvant and adjuvant settings, as well as to provide a clinical framework for use of this data based on our own institutional protocol for gastric cancer. Major studies reviewed include the SWOG/INT 0116, Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC), CLASSIC, ACTS-GC, Adjuvant Chemoradiation Therapy in Stomach Cancer (ARTIST) and Trastuzumab for Gastric Cancer trials. Although these studies have demonstrated that multiple approaches in terms of the timing and therapy for gastric cancer are effective, no standard of care is widely accepted and questions regarding the optimal timing of chemotherapy, the benefit of radiotherapy, the minimum required extent of lymphadenectomy and optimal chemotherapy regimen still exist. Protocols from the upcoming ARTIST II, CRITICS, TOPGEAR, Neo-AEGIS and MAGIC-B studies are outlined, and results from these studies will provide critical information regarding optimal timing and treatment regimen. Additionally, the future directions of gastric cancer research predicated on molecular profiling and tailored therapies based on targetable genetic alterations in individual patient's tumors are addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.